Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation.

Nat Commun · 2023 · PMC10725470 · PMID 38104114

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, in our subgroup analysis (Table 3 ), the elevated risk of VBR did not reach statistical significance for fully vaccinated or boosted patients who initiated nirmatrelvir/ritonavir within 1 day of the index date.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.